e3 Pharmaceuticals
e3 Pharmaceuticals focuses on clinical research exploring how the natural element lithium can support human health.
e3's product is the lithium aspartate dietary supplement, Lithitate®.
​
Information on lithium's ability to support human health as well as links to supporting, peer-reviewed research studies can be found on Lithitate.com.
​
Who We Are:
Dr. Thomas Guttuso, Jr., MD is President of e3 Pharmaceuticals since its inception in 2017. Dr. Guttuso is currently a Professor of Neurology at the University at Buffalo and Co-Director of the Movement Disorder Center. He is a member of the Parkinson Study Group and the International Parkinson and Movement Disorders Society. Dr. Guttuso is also author of the book: The Promise of Lithium.​
Advisory Board:
Karl Kieburtz, MD has been the Chief Medical Officer at PhotoPharmics since 2021 and President of CLINTREX® since its inception in 2008. He is also the Robert J Joynt Professor in the Department of Neurology, Professor in the Department of Public Health Science and Environmental Medicine and was the founding Director of the Center for Human Experimental Therapeutics (CHET) at the University of Rochester.
​
CLINTREX® is a pharmaceutical advisory company that is comprised of an integrated team of internationally-renowned and respected experts in the regulatory, clinical, clinical trial, bio-statistical, and basic science issues related to the development of new treatments for neurodegenerative and other CNS disorders.
Ms. Kamp is the Vice President of Operations at CLINTREX® and is responsible for clinical operations. She is on the faculty of the University of Rochester and serves as Executive Director of the Clinical Materials Services Unit (CMSU) in the Center for Human Experimental Therapeutics. She received a Masters Degree in Business Administration from the William E. Simon School of Business Administration, at the University of Rochester. She has had more than 25 years experience in pharmaceutical-based research including project management, data management, operations, budgets, contracts, site management, site activation, and clinical drug/device supply services. Ms. Kamp has overseen the operations of more than 50 multi-center international clinical trials and managed over 23 INDs from initial submission through annual reporting and creation of the final Clinical Summary Reports (CSRs).
Kurt R. Karst provides regulatory counsel to pharmaceutical manufacturers on Hatch-Waxman patent and exclusivity, drug development and pediatric testing. He helps clients develop strategies for product lifecycle management, obtaining approval, managing post-marketing issues, and defining periods of exclusivity. As the co-founder and primary author of Hyman, Phelps & McNamara’s FDA Law Blog, Mr. Karst often leads the response to new rules and regulations, sharing his interpretation with the broader legal community.
Contact Us:
Baird Research Park; 1576 Sweet Home Road; Amherst, NY 14228-2710